The Medical Letter on Drugs and Therapeutics
Opioids for Pain
December 12, 2022 (Issue: 1665)A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
- D Dowell et al. CDC clinical practice guideline for prescribing opioids for pain–United States, 2022. MMWR Recomm Rep 2022; 71:1.
- Nonopioid drugs for pain. Med Lett Drugs Ther 2022; 64:33.
- AK Chang et al. Effect of a single dose of oral opioid and nonopioid analgesics on acute extremity pain in the emergency department: a randomized clinical trial. JAMA 2017; 318:1661.
- R Chou et al. Treatments for acute pain: a systematic review [Internet]. Comparative effectiveness review #240. Rockville (MD): Agency for Healthcare Research and Quality (US); December 2020. Report No.: 20(21)-EHC006. Available at: http://bit.ly/3UCZzvR. Accessed November 21, 2022.
- CJ Derry et al. Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Database Syst Rev 2014 Dec; 2014 (12):CD009281.
- M Miller et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med 2015; 175:608.
- RA Deyo et al. Association between initial opioid prescribing patterns and subsequent long-term use among opioid-naïve patients: a statewide retrospective cohort study. J Gen Intern Med 2017; 32:21.
- A Shah et al. Characteristics of initial prescription episodes and likelihood of long-term opioid use - United States, 2006-2015. MMWR Morb Mortal Wkly Rep 2017; 66:265.
- Drugs for opioid use disorder. Med Lett Drugs Ther 2017; 59:89.
- R Chou et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways of Prevention Workshop. Ann Intern Med 2015; 162:276.
- DR Veiga et al. Effectiveness of opioids for chronic noncancer pain: a two-year multicenter, prospective cohort study with propensity score matching. J Pain 2019; 20:706.
- EE Krebs et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA 2018; 319:872.
- Methylnaltrexone (Relistor) for opioid-induced constipation. Med Lett Drugs Ther 2008; 50:63.
- Naloxegol (Movantik) for opioid-induced constipation. Med Lett Drugs Ther 2015; 57:135.
- Naldemedine (Symproic) for opioid-induced constipation. Med Lett Drugs Ther 2017; 59:196.
- Lubiprostone (Amitiza) for opioid-induced constipation. Med Lett Drugs Ther 2013; 55:47.
- M Lee et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011; 14:145.
- MJ Brennan. The effect of opioid therapy on endocrine function. Am J Med 2013; 126:S12.
- FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. March 22, 2016. Available at: http://bit.ly/3AiIT4w. Accessed November 21, 2022.
- FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. August 31, 2016. Available at: http://bit.ly/3UInBW8. Accessed November 21, 2022.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2021 October 20 (epub). Available at www.medicalletter.org/downloads/CYP_PGP_Tables.pdf. Accessed November 21, 2022.
- Drug interactions: opioids and oral P2Y12 platelet inhibitors. Med Lett Drugs Ther 2019; 61:31.
- RHM Furtado et al. Morphine and cardiovascular outcomes among patients with non-ST-segment elevation acute coronary syndromes undergoing coronary angiography. J Am Coll Cardiol 2020; 75:289.
- VE Whiteman et al. Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. J Pregnancy 2014; 2014:906723.
- RE Azuine et al. Prenatal risk factors and perinatal and postnatal outcomes associated with maternal opioid exposure in an urban, low-income, multiethnic US population. JAMA Netw Open 2019; 2:e196405.
- Substance Abuse and Mental Health Services Administration. Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. HHS Publication No. (SMA) 18-5054. Rockville, MD: 2018. Available at: http://bit.ly/3OaIZkr. Accessed November 21, 2022.
- HHS. Naloxone: the opioid reversal drug that saves lives. Available at: https://bit.ly/3k68NiV. Accessed November 21, 2022.
- Nalmefene returns for reversal of opioid overdose. Med Lett Drugs Ther 2022; 64:141.
- FDA warns against use of codeine and tramadol in children and breastfeeding women. Med Lett Drugs Ther 2017; 59:86.
- In brief: Heat and transdermal fentanyl. Med Lett Drugs Ther 2009; 51:64.
- FDA Drug Safety Communication: FDA requiring color changes to Duragesic (fentanyl) pain patches to aid safety―emphasizing that accidental exposure to used patches can cause death. September 23, 2013. Available at: http://bitly/3GkUxzO. Accessed November 21, 2022.
- Extended-release hydrocodone (Zohydro ER) for pain. Med Lett Drugs Ther 2014; 56:45.
- Extended-release hydrocodone (Hysingla ER) for pain. Med Lett Drugs Ther 2015; 57:71.
- Extended-release hydromorphone (Exalgo) for pain. Med Lett Drugs Ther 2011; 53:62.
- H Binsfeld et al. A randomized study to demonstrate noninferiority of once-daily OROS hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Pract 2010; 10:404.
- E Bruera et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004; 22:185.
- M Faul et al. Methadone prescribing and overdose and the association with Medicaid preferred drug list policies — United States, 2007–2014. MMWR Morb Mortal Wkly Rep 2017; 66:320.
- MJ Krantz et al. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150:387.
- Oliceridine (Olinvyk) - a new opioid for severe pain. Med Lett Drugs Ther 2021; 63:37.
- Oral oxymorphone (Opana). Med Lett Drugs Ther 2007; 49:3.
- FDA. Oxymorphone (marketed as Opana ER) information. February 6, 2018. Available at: https://bit.ly/3Gv2UJa. Accessed: November 21, 2022.
- Abuse-deterrent opioid formulations. Med Lett Drugs Ther 2015; 57:119.
- Arymo ER – a new abuse-deterrent morphine formulation. Med Lett Drugs Ther 2017; 59:68.
- A new abuse-deterrent opioid – Xtampza ER. Med Lett Drugs Ther 2016; 58:77.
- Tapentadol (Nucynta) – a new analgesic. Med Lett Drugs Ther 2009; 51:61.
- M Afilalo and B Morlion. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician 2013; 16:27.
- Tramadol/celecoxib (Seglentis) for pain. Med Lett Drugs Ther 2022; 64:58.
- RM Duehmke et al. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev 2017; 6:CD003726.
- JP Fournier et al. Tramadol use and the risk of hospitalization for hypoglycemia in patients with noncancer pain. JAMA Intern Med 2015; 175:186.
- Transdermal buprenorphine (Butrans) for chronic pain. Med Lett Drugs Ther 2011; 53:31.
- Buprenorphine buccal film (Belbuca) for chronic pain. Med Lett Drugs Ther 2016; 58:47.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.